Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepagina
  2. Aandelen
  3. Frankrijk
  4. Euronext Paris
  5. DBV Technologies
  6. Nieuws
  7. Persberichten
    DBV   FR0010417345

DBV TECHNOLOGIES

(DBV)
  Rapport
Real Time Euronext Paris  -  17:35 02-12-2022
2.788 EUR   +1.16%
02/12Europese aandelen bewegen lager en eindigen sterke maand, week lager
MT
01/12Europese aandelen bewegen donderdag hoger nu de EU het plafond voor Russische olie nadert
MT
29/11Inflatiedaling in Duitsland en Spanje stimuleert Europese aandelen
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť DBV TECHNOLOGIES
22/11DBV Technologies to Participate in Upcoming Investor Conference
GL
22/11DBV Technologies to Participate in Upcoming Investor Conference
AQ
09/11DBV Technologies to Highlight New Clinical Data at ACAAI 2022
GL
09/11DBV Technologies to Highlight New Clinical Data at ACAAI 2022
AQ
03/11DBV TECHNOLOGIES S.A. Management's Discussion and Analysis of Financial Condition and ..
AQ
03/11DBV Technologies Reports Third Quarter Financial Results and Business Update
GL
03/11DBV Technologies Reports Third Quarter Financial Results and Business Update
AQ
31/10DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business ..
GL
31/10DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business ..
AQ
04/10Dbv Technologies S.a. : Change in Directors or Principal Officers, Regulation FD Disclosur..
AQ
03/10DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointm..
GL
03/10DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointm..
AQ
22/09Dbv Technologies S.a. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
21/09DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial
GL
21/09DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial
AQ
08/09Dbv Technologies S.a. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/09DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Via..
GL
07/09DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Via..
AQ
02/09DBV Technologies to Present at Upcoming Investor Conferences
GL
02/09DBV Technologies to Present at Upcoming Investor Conferences
AQ
01/08Dbv Technologies : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
01/08DBV TECHNOLOGIES S.A. Management's Discussion and Analysis of Financial Condition and ..
AQ
01/08DBV Technologies Reports Second Quarter 2022 Financial Results
GL
01/08DBV Technologies Reports Second Quarter 2022 Financial Results
GL
27/07Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
GL
29/06DBV Technologies to Participate in Upcoming EAACI 2022 Congress
GL
29/06DBV Technologies to Participate in Upcoming EAACI 2022 Congress
AQ
16/06DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York
GL
16/06Dbv Technologies : to Present at the JMP Securities Life Sciences Conference in New York
PU
13/06Dbv Technologies : Announces Private Placement Financing of $194 Million - Form 8-K
PU
13/06Dbv Technologies S.a. : Entry into a Material Definitive Agreement, Unregistered Sale of E..
AQ
09/06DBV Technologies Announces Private Placement Financing of $194 Million
GL
09/06DBV Technologies Announces Private Placement Financing of $194 Million
AQ
07/06Dbv Technologies : Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaski..
PU
07/06Dbv Technologies S.a. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/06Dbv Technologies : Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaski..
PU
07/06DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viask..
GL
07/06DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viask..
AQ
16/05Dbv Technologies S.a. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
12/05DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeti..
GL
12/05DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeti..
AQ
05/05DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through it..
GL
05/05DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through it..
AQ
02/05DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
GL
02/05Dbv Technologies S.a. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
02/05DBV TECHNOLOGIES S.A. Management's Discussion and Analysis of Financial Condition and ..
AQ
02/05DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial ..
GL
02/05DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial ..
AQ
26/04DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Dev..
AQ
26/04Dbv Technologies : AGM 2022 – Definitive Proxy Statement
PU
25/04Correction : DBV Technologies to Report First Quarter 2022 Financial Results and Recent Bu..
AQ
22/04Dbv Technologies : AGM 2022 – Statutory Auditors' special report on regulated agreem..
PU
22/04Dbv Technologies : AGM 2022 – Statutory auditors' report on the consolidated financi..
PU
22/04Dbv Technologies : AGM 2022 – Statutory auditors' report on the financial statements..
PU
22/04Ordinary and Extraordinary General Meeting of May 12, 2022; Procedures for Obtaining Pr..
AQ
21/04Ordinary and Extraordinary General Meeting of May 12, 2022
AQ
21/04Dbv Technologies : AGM 2022 – Proxy Card
PU
21/04Dbv Technologies : AGM 2022 – Notice of meeting
PU
15/03DBV Technologies to Present at the Oppenheimer's 32nd Annual Healthcare Conference
AQ
14/03DBV Technologies to Present at the Oppenheimer's 32nd Annual Healthcare Conference
AQ
09/03Dbv Technologies S A : Montrouge, France, March 9, 2022 - Form 8-K
PU
09/03Dbv Technologies S.a. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
AQ
09/03DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021 Universal..
AQ
09/03DBV TECHNOLOGIES S.A. Management's Discussion and Analysis of Financial Condition and ..
AQ
03/03Dbv Technologies S A : Reports Full Year 2021 Financial Results and Recent Business Update..
PU
03/03DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates
GL
24/02DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on Mar..
GL
24/02DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on Mar..
AQ
22/02DBV Technologies to Participate in Upcoming AAAAI 2022 Congress
AQ
14/02DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference
AQ
21/01Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AQ
07/01DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference
AQ
2021DBV Technologies Provides Update on Investigational Viaskinâ„Ę Peanut
AQ
2021Dbv Technologies : Provides Update on Investigational Viaskin™ Peanut - Form 8-K
PU
2021Dbv Technologies S.a. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
1  2  3  4  5  6  7  8  9Volgende
Volgende evenement op DBV TECHNOLOGIES